Jupiter Neurosciences Files 8-K on Agreements and Obligations
Ticker: JUNS · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1679628
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
JUPITER NEUROSCIENCES (JUPITER) filed an 8-K detailing material agreements, financial obligations, and equity sales.
AI Summary
On October 24, 2025, Jupiter Neurosciences, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities. This filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This 8-K filing indicates significant financial and contractual developments for Jupiter Neurosciences, Inc., potentially impacting its operational and financial standing.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-41265 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-4828381 — IRS EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- JUPITER NEUROSCIENCES, INC. (company) — Registrant
- October 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 47-4828381 (identifier) — IRS Employer Identification Number
- Jupiter Orphan Therapeutics, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Jupiter Neurosciences, Inc. on October 24, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details are not provided in the provided text, only that it is an 'Item Information' category.
What type of direct financial obligation was created by Jupiter Neurosciences, Inc.?
The filing states the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant,' but the specific details of the obligation are not elaborated in the provided text.
When did Jupiter Neurosciences, Inc. change its name from Jupiter Orphan Therapeutics, Inc.?
The date of the name change from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc. was July 13, 2016.
What is the SIC code for Jupiter Neurosciences, Inc.?
The Standard Industrial Classification (SIC) code for Jupiter Neurosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What are the key items reported in this 8-K filing?
The key items reported are: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 4,524 words · 18 min read · ~15 pages · Grade level 18.2 · Accepted 2025-10-27 17:25:41
Key Financial Figures
- $20.0 million — as the right to sell to Yorkville up to $20.0 million of its common stock, par value $0.0001
- $0.0001 — million of its common stock, par value $0.0001 per share (the "Common Stock"), subject
- $6.0 m — agreed to advance to the Company up to $6.0 million, less certain amounts as describe
- $3,720,000 — first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October
- $4.0 m — ertible Note in the principal amount of $4.0 million, which was issued with an "origin
- $280,000 — nal issue discount" ("OID") of 7.0% (or $280,000) and is initially convertible into Comm
- $1.50 — on Stock at a fixed conversion price of $1.50 per share (subject to adjustment as pro
- $1,860,000 — f the Pre-Paid Advance in the amount of $1,860,000 will be disbursed to the Company on the
- $2.0 m — ertible Note in the principal amount of $2.0 million, which will likewise be issued wi
- $140,000 — n "original issue discount" of 7.0% (or $140,000) and will also be initially convertible
- $25,000 — cash "structuring fee" in the amount of $25,000 and (ii) upon execution of the SEPA, is
- $200,000 — a total aggregate dollar value equal to $200,000, or 1.0% of Yorkville's $20.0 million a
- $1.5162 — ommitment Share valued at approximately $1.5162 per share, representing the VWAP on Oct
- $18,000 — ny through any Pre-Paid Advance and (b) $18,000 per month, on an accrual basis, for a p
- $5.0 million — able at such time as the Company raises $5.0 million or more in additional financing. This
Filing Documents
- form8-k.htm (8-K) — 79KB
- ex4-1.htm (EX-4.1) — 142KB
- ex10-1.htm (EX-10.1) — 325KB
- ex10-2.htm (EX-10.2) — 103KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-25-019783.txt ( ) — 968KB
- juns-20251024.xsd (EX-101.SCH) — 3KB
- juns-20251024_lab.xml (EX-101.LAB) — 33KB
- juns-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 27, 2025 Jupiter Neurosciences, Inc. By: /s/ Christer Rosn Name: Christer Rosn Title: Chairman and Chief Executive Officer